Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Melani

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Blood Advances|February 10, 2022
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphomaRahul Lakhotia, Christopher Melani, Kieron Dunleavy, et al.
Haematologica|May 12, 2018
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision makingChristopher Melani, Ranjana Advani, Mark Roschewski, et al.
Blood Advances|June 30, 2023
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-RRahul Lakhotia, Kieron Dunleavy, Jeremy S Abramson, et al.
The Lancet. Haematology|April 3, 2023
Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trialChristopher Melani, Kennichi Dowdell, Stefania Pittaluga, et al.
ACS Pharmacology & Translational Science|December 18, 2025
An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) InhibitorsAna Corrionero, Xiaohu Zhang, Patricia Alfonso, et al.
The New England Journal of Medicine|July 6, 2017
PD-1 Blockade in Mediastinal Gray-Zone LymphomaChristopher Melani, Ajay Major, Jeffrey Schowinsky, et al.
The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Cancer Cell|May 30, 2017
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS LymphomaMichail S Lionakis, Kieron Dunleavy, Mark Roschewski, et al.
The New England Journal of Medicine|June 20, 2024
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell LymphomaChristopher Melani, Rahul Lakhotia, Stefania Pittaluga, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Blood Advances|February 10, 2022
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphomaRahul Lakhotia, Christopher Melani, Kieron Dunleavy, et al.
Haematologica|May 12, 2018
End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision makingChristopher Melani, Ranjana Advani, Mark Roschewski, et al.
Blood Advances|June 30, 2023
Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-RRahul Lakhotia, Kieron Dunleavy, Jeremy S Abramson, et al.
The Lancet. Haematology|April 3, 2023
Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trialChristopher Melani, Kennichi Dowdell, Stefania Pittaluga, et al.
ACS Pharmacology & Translational Science|December 18, 2025
An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) InhibitorsAna Corrionero, Xiaohu Zhang, Patricia Alfonso, et al.
The New England Journal of Medicine|July 6, 2017
PD-1 Blockade in Mediastinal Gray-Zone LymphomaChristopher Melani, Ajay Major, Jeffrey Schowinsky, et al.
The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2020
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt LymphomaMark Roschewski, Kieron Dunleavy, Jeremy S Abramson, et al.
Cancer Cell|May 30, 2017
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS LymphomaMichail S Lionakis, Kieron Dunleavy, Mark Roschewski, et al.
The New England Journal of Medicine|June 20, 2024
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell LymphomaChristopher Melani, Rahul Lakhotia, Stefania Pittaluga, et al.
Pageof 3